Amanda Waddell1, Jefferson E Vallance, Preston D Moore, Amy T Hummel, David Wu, Shiva K Shanmukhappa, Lin Fei, M Kay Washington, Phillip Minar, Lori A Coburn, Susumu Nakae, Keith T Wilson, Lee A Denson, Simon P Hogan, Michael J Rosen. 1. *Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; †Division of Pediatric Gastroenterology, Hepatology and Nutrition, Vanderbilt University Medical Center, Nashville, Tennessee; ‡Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; §Division of Pathology and Laboratory Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; ‖Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; ¶Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee; **Veterans Affairs Tennessee Valley Healthcare System, Nashville, Tennessee; ††Division of Gastroenterology, Hepatology and Nutrition, Vanderbilt University Medical Center, Nashville, Tennessee; and ‡‡The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Abstract
BACKGROUND: IL-33, a member of the IL-1 cytokine family that signals through ST2, is upregulated in ulcerative colitis (UC); however, the role of IL-33 in colitis remains unclear. IL-33 augments type 2 immune responses, which have been implicated in UC pathogenesis. We sought to determine the role of IL-33 signaling in oxazolone (OXA) colitis, a type 2 cytokine-mediated murine model of UC. METHODS: Colon mucosal IL-33 expression was compared between pediatric and adult UC and non-IBD patients using immunohistochemistry and real-time PCR. OXA colitis was induced in WT, IL-33, and ST2 mice, and histopathology, cytokine levels, and goblet cells were assessed. Transepithelial resistance was measured across IL-33-treated T84 cell monolayers. RESULTS: Colon mucosal IL-33 was increased in pediatric patients with active UC and in OXA colitis. IL-33 and ST2 OXA mice exhibited increased disease severity compared with WT OXA mice. OXA induced a mixed mucosal cytokine response, but few differences were observed between OXA WT and IL-33 or ST2 mice. Goblet cells were significantly decreased in IL-33 and ST2 OXA compared with WT OXA mice. IL-33 augmented transepithelial resistance in T84 cells, and this effect was blocked by the ERK1/2 inhibitor PD98,059. CONCLUSIONS: OXA colitis is exacerbated in IL-33 and ST2 mice. Increased mucosal IL-33 in human UC and murine colitis may be a homeostatic response to limit inflammation, potentially through effects on epithelial barrier function. Further investigation of IL-33 protective mechanisms would inform the development of novel therapeutic approaches.
BACKGROUND:IL-33, a member of the IL-1 cytokine family that signals through ST2, is upregulated in ulcerative colitis (UC); however, the role of IL-33 in colitis remains unclear. IL-33 augments type 2 immune responses, which have been implicated in UC pathogenesis. We sought to determine the role of IL-33 signaling in oxazolone (OXA) colitis, a type 2 cytokine-mediated murine model of UC. METHODS: Colon mucosal IL-33 expression was compared between pediatric and adult UC and non-IBD patients using immunohistochemistry and real-time PCR. OXAcolitis was induced in WT, IL-33, and ST2mice, and histopathology, cytokine levels, and goblet cells were assessed. Transepithelial resistance was measured across IL-33-treated T84 cell monolayers. RESULTS: Colon mucosal IL-33 was increased in pediatric patients with active UC and in OXAcolitis. IL-33 and ST2OXAmice exhibited increased disease severity compared with WTOXAmice. OXA induced a mixed mucosal cytokine response, but few differences were observed between OXAWT and IL-33 or ST2mice. Goblet cells were significantly decreased in IL-33 and ST2OXA compared with WTOXAmice. IL-33 augmented transepithelial resistance in T84 cells, and this effect was blocked by the ERK1/2 inhibitor PD98,059. CONCLUSIONS:OXAcolitis is exacerbated in IL-33 and ST2mice. Increased mucosal IL-33 in human UC and murinecolitis may be a homeostatic response to limit inflammation, potentially through effects on epithelial barrier function. Further investigation of IL-33 protective mechanisms would inform the development of novel therapeutic approaches.
Authors: Paul Rutgeerts; William J Sandborn; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Suzanne Travers; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel Present; Bruce E Sands; Jean Frédéric Colombel Journal: N Engl J Med Date: 2005-12-08 Impact factor: 91.245
Authors: Jochen Schmitz; Alexander Owyang; Elizabeth Oldham; Yaoli Song; Erin Murphy; Terril K McClanahan; Gerard Zurawski; Mehrdad Moshrefi; Jinzhong Qin; Xiaoxia Li; Daniel M Gorman; J Fernando Bazan; Robert A Kastelein Journal: Immunity Date: 2005-11 Impact factor: 31.745
Authors: Damo Xu; Hui-Rong Jiang; Peter Kewin; Yubin Li; Rong Mu; Alasdair R Fraser; Nick Pitman; Mariola Kurowska-Stolarska; Andrew N J McKenzie; Iain B McInnes; Foo Y Liew Journal: Proc Natl Acad Sci U S A Date: 2008-07-30 Impact factor: 11.205
Authors: Elizabeth E Forbes; Katherine Groschwitz; J Pablo Abonia; Eric B Brandt; Elizabeth Cohen; Carine Blanchard; Richard Ahrens; Luqman Seidu; Andrew McKenzie; Richard Strait; Fred D Finkelman; Paul S Foster; Klaus I Matthaei; Marc E Rothenberg; Simon P Hogan Journal: J Exp Med Date: 2008-03-31 Impact factor: 14.307